J C Davis

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A practical approach to gout. Current management of an 'old' disease
    J C Davis
    Division of Rheumatology, UCSF 94143 0633, USA
    Postgrad Med 106:115-6, 119-23. 1999
  2. pmc Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
    J C Davis
    University of California, San Francisco, 533 Parnassus Ave Rm U 383 Box 0633, San Francisco, California, USA
    Ann Rheum Dis 64:1557-62. 2005
  3. ncbi request reprint Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    J C Davis
    University of California, San Francisco, 533 Parnassus Avenue, Box 0633, Room U 386, San Francisco, CA 94143 0633 USA
    Ann Rheum Dis 67:346-52. 2008
  4. ncbi request reprint Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 53:494-501. 2005
  5. ncbi request reprint Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept
    John C Davis
    Division of Rheumatology, University of California, San Francisco 94143 0633, USA
    J Rheumatol 32:1751-4. 2005
  6. ncbi request reprint Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 57:1050-7. 2007
  7. ncbi request reprint Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 48:3230-6. 2003
  8. ncbi request reprint New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate
    John C Davis
    Division of Rheumatology, Department of Medicine, University of California San Francisco, 533 Parnassus Avenue, Box 0633, San Francisco, CA 94143, USA
    Rheum Dis Clin North Am 29:481-94, viii. 2003
  9. ncbi request reprint Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis
    John C Davis
    Lupus Clinic, University of California, San Francisco, USA
    Semin Arthritis Rheum 34:668-77. 2005
  10. ncbi request reprint The role of etanercept in ankylosing spondylitis
    J C Davis
    Division of Rheumatology, University of California, San Francisco, 94143, USA
    Clin Exp Rheumatol 20:S111-5. 2002

Research Grants

Detail Information

Publications52

  1. ncbi request reprint A practical approach to gout. Current management of an 'old' disease
    J C Davis
    Division of Rheumatology, UCSF 94143 0633, USA
    Postgrad Med 106:115-6, 119-23. 1999
    ..Acute episodes are treated with NSAIDs or colchicine. Low-dose therapy with these agents can also prevent recurrent attacks. Most patients with gout need long-term treatment with either uricosuric agents or xanthine oxidase inhibitors...
  2. pmc Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
    J C Davis
    University of California, San Francisco, 533 Parnassus Ave Rm U 383 Box 0633, San Francisco, California, USA
    Ann Rheum Dis 64:1557-62. 2005
    ..To evaluate the continued safety and durability of clinical response in patients with ankylosing spondylitis receiving etanercept...
  3. ncbi request reprint Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    J C Davis
    University of California, San Francisco, 533 Parnassus Avenue, Box 0633, Room U 386, San Francisco, CA 94143 0633 USA
    Ann Rheum Dis 67:346-52. 2008
    ..Evaluate long-term safety and efficacy of etanercept treatment in patients with ankylosing spondylitis (AS)...
  4. ncbi request reprint Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 53:494-501. 2005
    ....
  5. ncbi request reprint Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept
    John C Davis
    Division of Rheumatology, University of California, San Francisco 94143 0633, USA
    J Rheumatol 32:1751-4. 2005
    ..To examine the baseline demographic and disease characteristics that might influence improvement as measured by the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) in patients with ankylosing spondylitis (AS)...
  6. ncbi request reprint Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 57:1050-7. 2007
    ..To evaluate the impact of adalimumab on health-related quality of life (HRQOL) in patients with active ankylosing spondylitis (AS)...
  7. ncbi request reprint Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 48:3230-6. 2003
    ..To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo-controlled, double-blind trial of adults with moderate to severe active ankylosing spondylitis (AS)...
  8. ncbi request reprint New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate
    John C Davis
    Division of Rheumatology, Department of Medicine, University of California San Francisco, 533 Parnassus Avenue, Box 0633, San Francisco, CA 94143, USA
    Rheum Dis Clin North Am 29:481-94, viii. 2003
    ..This article reviews the rationale, clinical efficacy, and safety reports of etanercept, thalidomide, and pamidronate in the treatment of patients who have AS...
  9. ncbi request reprint Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis
    John C Davis
    Lupus Clinic, University of California, San Francisco, USA
    Semin Arthritis Rheum 34:668-77. 2005
    ..Research in the molecular and cellular events of AS has uncovered a distinct role for the proinflammatory cytokine, tumor necrosis factor (TNF), in the pathogenesis of this disease...
  10. ncbi request reprint The role of etanercept in ankylosing spondylitis
    J C Davis
    Division of Rheumatology, University of California, San Francisco, 94143, USA
    Clin Exp Rheumatol 20:S111-5. 2002
    ..Future studies with larger numbers of patients over long periods of time will eventually determine the long-term success and safety of these agents...
  11. ncbi request reprint Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
    Jennifer D Gorman
    Division of Rheumatology, University of California, San Francisco 94143, USA
    N Engl J Med 346:1349-56. 2002
    ....
  12. ncbi request reprint The treatment of ankylosing spondylitis
    K J Scalapino
    Division of Rheumatology, The University of California San Francisco, 533 Parnassus Avenue, Box 0633, Room U383, San Francisco, CA 94143, USA
    Clin Exp Med 2:159-65. 2003
    ..This paper will provide a comprehensive review of these treatments which focusing on evidence based medicine for the daily clinical practice of rheumatology...
  13. ncbi request reprint Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis
    Cailin Henderson
    Division of Rheumatology Clinical Trials Center, University of California, San Francisco, CA 94143 0633, USA
    Nat Clin Pract Rheumatol 2:211-8. 2006
    ..This review discusses the data from clinical trials that have assessed the use of TNF inhibitors in patients with AS, and briefly outlines other biologic therapies that have been studied...
  14. pmc A quality indicator set for systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143 0920, USA
    Arthritis Rheum 61:370-7. 2009
    ..To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE)...
  15. ncbi request reprint Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus
    J C Davis
    Division of Rheumatology, University of California, San Francisco 94143, USA
    J Rheumatol 28:95-101. 2001
    ..Efficacy was not formally evaluated in this single dose study. CONCLUSION: IDEC-131 (humanized Mab against CD40L) administered in a single intravenous infusion at doses of 0.05-15.0 mg/kg is safe and well tolerated in patients with SLE...
  16. pmc Definition of disease duration in ankylosing spondylitis: reassessing the concept
    J C Davis
    Division of Rheumatology, University of California San Francisco, San Francisco, California, USA
    Ann Rheum Dis 65:1518-20. 2006
    ..Such uniformity in data collection will ensure comparability across studies and facilitate future research...
  17. doi request reprint Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic
    John C Davis
    University of California San Francisco, San Francisco, CA, USA
    Semin Arthritis Rheum 38:83-100. 2008
    ..The aim of this review was to evaluate the classification, genetic susceptibility, pathology, and response to treatment of spondyloarthritis (SpA)...
  18. ncbi request reprint Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort
    L S Gensler
    University of California San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143 0633, USA
    Ann Rheum Dis 67:233-7. 2008
    ..The purpose of this study was to evaluate clinical, functional and radiographic differences between patients with JoAS and AoAS in a large cohort of patients with long-standing disease...
  19. pmc Type I interferon correlates with serological and clinical manifestations of SLE
    M C Dall'era
    University of California, San Francisco, San Francisco, CA 94143, USA
    Ann Rheum Dis 64:1692-7. 2005
    ..Previous clinical studies in humans and murine models suggest that type I interferons (IFNs) are important for the initiation and potentiation of SLE activity...
  20. pmc Lamivudine is not effective in primary Sjögren's syndrome
    B Gescuk
    Clinical Trials Center, Division of Rheumatology, University of California, San Francisco, 533 Parnassus Avenue Box 0633 Room U383, San Francisco, CA 94143 0633, USA
    Ann Rheum Dis 64:1326-30. 2005
    ..Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome...
  21. pmc Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis
    Tamar F Brionez
    Department of Medicine, Division of Rheumatology, University of Texas Houston, 6431 Fannin, Houston, Texas 77030, USA
    Arthritis Res Ther 11:R182. 2009
    ..The purpose of this study was to investigate the role of psychological variables in self-reported functional limitation in patients with AS, while controlling for demographic and medical variables...
  22. ncbi request reprint MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis
    Miriam A Bredella
    Department of Radiology, University of California, San Francisco, San Francisco, CA, USA
    AJR Am J Roentgenol 187:1420-6. 2006
    ....
  23. ncbi request reprint Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial
    Kenneth C Kalunian
    University of California, Los Angeles School of Medicine, USA
    Arthritis Rheum 46:3251-8. 2002
    ..To evaluate the safety and efficacy of a humanized monoclonal antibody against CD154 (IDEC-131) in patients with active systemic lupus erythematosus (SLE)...
  24. pmc Psychological correlates of self-reported disease activity in ankylosing spondylitis
    Tamar F Brionez
    Department of Medicine, Division of Rheumatology, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    J Rheumatol 37:829-34. 2010
    ..To investigate the role of psychological variables in self-reported disease activity in patients with ankylosing spondylitis (AS), while controlling for demographic and medical variables...
  25. ncbi request reprint Recognition and treatment of juvenile-onset spondyloarthritis
    Lianne Gensler
    Clinical Research Center, University of California San Francisco, 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Curr Opin Rheumatol 18:507-11. 2006
    ..The purpose of this review is to discuss the classification, diagnosis and management of juvenile-onset spondyloarthritis...
  26. doi request reprint Development and validation of a case ascertainment tool for ankylosing spondylitis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Care Res (Hoboken) 62:19-27. 2010
    ..We tested questions derived from a comprehensive literature review and an advisory board in a case-control study designed to identify patients with AS from among patients with chronic back pain (CBP)...
  27. pmc Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort
    Wonuk Lee
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Rheum Dis 66:633-8. 2007
    ....
  28. ncbi request reprint Novel therapeutic agents for systemic lupus erythematosus
    Bryan D Gescuk
    Division of Rheumatology, University of California, San Francisco 94143, USA
    Curr Opin Rheumatol 14:515-21. 2002
    ..While some of these new therapies target specific inflammatory mechanisms in SLE (anti-CD40L monoclonal antibody), others work by nonspecific inhibition of the immune system (immunoablation)...
  29. ncbi request reprint Systemic lupus erythematosus. How to manage, when to refer
    Maria Dall'Era
    Division of Rheumatology, Department of Medicine Clinical Trials Center, University of California, San Francisco, School of Medicine, 533 Parnassus Ave, San Francisco, CA 94143, USA
    Postgrad Med 114:31-7, 40. 2003
    ..The section on therapy constitutes a practical resource for primary care physicians who care for patients with SLE...
  30. doi request reprint Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study
    Vivien M Hsu
    Division of Rheumatology, UMDNJ Scleroderma Program, New Brunswick, NJ 08903, USA
    Clin Trials 7:85-9. 2010
    ....
  31. ncbi request reprint Etanercept in adult patients with early onset ankylosing spondylitis
    Robert D Inman
    Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 33:1634-6. 2006
    ..To determine whether twice-weekly subcutaneous etanercept improves the signs and symptoms of adult patients with early onset ankylosing spondylitis (AS)...
  32. ncbi request reprint Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis
    Astrid J B Wanders
    University Hospital Maastricht, Maastricht, The Netherlands
    Arthritis Rheum 51:1-8. 2004
    ....
  33. ncbi request reprint A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    John H Stone
    The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:902-10. 2005
    ..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)...
  34. ncbi request reprint Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    Philip Seo
    Johns Hopkins University, Baltimore, Maryland
    Arthritis Rheum 52:2168-78. 2005
    ..To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life...
  35. ncbi request reprint International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures
    Dafna D Gladman
    Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 34:1733-9. 2007
    ..To determine whether the axial measures used in primary ankylosing spondylitis (AS) were reproducible for both AS and psoriatic arthritis (PsA) with axial disease...
  36. ncbi request reprint Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis
    Walter P Maksymowych
    Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2S2, Canada
    J Rheumatol 32:1911-7. 2005
    ..The low sensitivity to change over time of plain radiographic instruments mandates a search for the effects of these therapies on possible biomarkers of cartilage damage...
  37. doi request reprint Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial
    Maxime Dougados
    Hôpital Cochin and University of Paris, Paris, France
    Arthritis Rheum 59:553-60. 2008
    ..To evaluate the feasibility/acceptability, reliability, external validity, and discriminant capacity of the Patient Acceptable Symptom State (PASS) concept in patients with active ankylosing spondylitis (AS)...
  38. ncbi request reprint Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial
    John H Stone
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 54:1608-18. 2006
    ..This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients...
  39. ncbi request reprint Spinal mobility measures in spondyloarthritis: application of the OMERACT filter
    John C Davis
    J Rheumatol 34:666-70. 2007
  40. ncbi request reprint Herpes zoster in immunocompromised patients: incidence, timing, and risk factors
    Peter K Wung
    Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 118:1416. 2005
    ..To evaluate the risk factors for herpes zoster as well as the incidence and timing of this complication in patients who were treated with immunosuppression because of active Wegener's granulomatosis...
  41. pmc Risk factors for functional limitations in patients with long-standing ankylosing spondylitis
    Michael M Ward
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD 20892, USA
    Arthritis Rheum 53:710-7. 2005
    ..To identify risk factors for functional limitations in patients with ankylosing spondylitis (AS) of at least 20 years' duration...
  42. ncbi request reprint Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial
    Desiree van der Heijde
    University Hospital Maastricht, Maastricht, The Netherlands
    Arthritis Rheum 54:2136-46. 2006
    ..To evaluate the safety and efficacy of adalimumab, a fully human recombinant IgG1 monoclonal antibody that specifically targets human tumor necrosis factor, in patients with active ankylosing spondylitis (AS)...
  43. ncbi request reprint Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)
    Michael M Ward
    J Rheumatol 33:978-82. 2006
  44. pmc Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis
    Michael M Ward
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892 1468, USA
    Arthritis Rheum 59:822-32. 2008
    ..We sought to identify specific occupational activities associated with functional limitations and radiographic damage in patients with longstanding ankylosing spondylitis (AS)...
  45. ncbi request reprint Breaking the ice: Testing tumor necrosis factor alpha blockade in lupus
    John C Davis
    Arthritis Rheum 50:3061-3. 2004
  46. doi request reprint Impact of ankylosing spondylitis on work and family life: comparisons with the US population
    Michael M Ward
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 59:497-503. 2008
    ..To examine the impact of ankylosing spondylitis (AS) on work disability, nonparticipation in the labor force, marriage, divorce, and childbearing...
  47. ncbi request reprint Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis
    Javier D Finkielman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 147:611-9. 2007
    ..The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial...
  48. ncbi request reprint Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
    Peter A Merkel
    Boston University School of Medicine, Vasculitis Center, E 5, 715 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 142:620-6. 2005
    ..Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known...
  49. pmc Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants
    Paul R Burton
    Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester LE1 7RH, UK
    Nat Genet 39:1329-37. 2007
    ....
  50. ncbi request reprint International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis
    Dafna D Gladman
    Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 34:1740-5. 2007
    ..To determine whether the assessments of peripheral joints and enthesitis were reproducible for both AS and PsA with axial disease, and whether dactylitis assessment is reproducible in patients with PsA...
  51. ncbi request reprint Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations
    Jodi K Sebastian
    Boston University, Boston, Massachusetts 02118, USA
    J Rheumatol 34:1027-31. 2007
    ..We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA...
  52. ncbi request reprint ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
    Javier D Finkielman
    Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Am J Med 120:643.e9-14. 2007
    ..The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results...

Research Grants1

  1. ANDROGEN AS ADJUNCT THERAPY IN RHEUMATOID ARTHRITIS
    John Davis; Fiscal Year: 2002
    ..abstract_text> ..